We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





World’s First Online Image-Based COVID-19 Diagnosis Improvement Tool Launched

By LabMedica International staff writers
Posted on 03 Apr 2020
Print article
Image: DetectED-X platform (Photo courtesy of DetectED-X)
Image: DetectED-X platform (Photo courtesy of DetectED-X)
DetectED-X (Sydney, Australia), a University of Sydney spinoff comprising radiation and imaging experts, has launched the world’s only online image-based COVID-19 diagnosis improvement tool for healthcare workers. The start-up has directed its breast cancer diagnosis tool at the coronavirus, drawing on pandemic cases globally with support from healthcare and industry leaders to ramp up COVID-19 detection. DetectED-X’s CovED platform, which can be accessed anywhere with an internet connection, is being provided for free and is supported by healthcare experts and leading corporations globally.

DetectED-X’s CovED follows on from the highly successful BreastScreen Reader Assessment Strategy (BREAST) platform, created in 2010 at the University of Sydney, which has been used internationally including in the US and Europe. The cloud-based life-saving technology can help doctors and radiologists diagnose cases faster and more accurately. Computed tomography (CT) lung scans, which produce cross-sectional images using X-rays and computers, are typically used after swabs are taken, to identify the extent and location of the disease; the CT scans produce images within minutes and are also able to diagnose COVID-19 in the very early stages that escape detection with nucleic acid tests.

DetectED-X’s approach, which includes algorithms to improve radiologist skills and identifying where errors were made on images in the online training sessions, has been shown to improve results significantly. Through CovED, individual clinicians can assess their performance on images on screen, and receive immediate feedback, including performance scores used in the industry. The image files personalized for each clinician are instantly returned showing any errors in their virtual diagnosis and the difficulty level is increased over time. As COVID-19 testing ramps up, the platform could facilitate rapid training where required – with modules able to be completed in as little as an hour – upskilling staff unfamiliar with lung radiology to prepare standardized reports for expert review.

“Our platform does not replace expert medical and radiologic training but CovED provides an effective way to recognize rapidly the appearances of COVID-19, which could be critical in a situation of too many patients and not enough expert radiologists, with the modules taking just 1-2 hours to complete,” said CEO Professor Patrick Brennan, medical radiation scientist and educator from the University of Sydney School of Health Sciences, Faculty of Medicine and Health. “This will be immediately crucial in developing countries, where numbers of radiologists are often insufficient – our tests will help people not only diagnose COVID-19 but also identify potentially life-threatening cases wherever they are.”

Related Links:
DetectED-X

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.